BR0315275A - Antibodies that bind to erythropoietin receptor - Google Patents

Antibodies that bind to erythropoietin receptor

Info

Publication number
BR0315275A
BR0315275A BR0315275-8A BR0315275A BR0315275A BR 0315275 A BR0315275 A BR 0315275A BR 0315275 A BR0315275 A BR 0315275A BR 0315275 A BR0315275 A BR 0315275A
Authority
BR
Brazil
Prior art keywords
antibodies
bind
erythropoietin receptor
relates
present
Prior art date
Application number
BR0315275-8A
Other languages
Portuguese (pt)
Inventor
Peter J Devries
Larry L Green
David H Ostrow
Edward B Reilly
James Wieler
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/269,711 external-priority patent/US20040071694A1/en
Priority claimed from US10/684,109 external-priority patent/US7396913B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR0315275A publication Critical patent/BR0315275A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

"ANTICORPOS QUE SE LIGAM A RECEPTOR DE ERITROPOIETINA". A presente invenção se refere a anticorpos e a fragmentos destes anticorpos que se ligam a um receptor de eritropoietina e o ativam. A presente invenção também se refere a métodos de modulação da atividade endógena de um receptor de eritropoietina em um mamífero empregando-se tais anticorpos, assim como a composições farmacêuticas contendo tais anticorpos."Antibodies that bind to the erythropoietin receptor". The present invention relates to antibodies and fragments of these antibodies that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using such antibodies, as well as pharmaceutical compositions containing such antibodies.

BR0315275-8A 2002-10-14 2003-10-14 Antibodies that bind to erythropoietin receptor BR0315275A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/269,711 US20040071694A1 (en) 2002-10-14 2002-10-14 Erythropoietin receptor binding antibodies
US10/684,109 US7396913B2 (en) 2002-10-14 2003-10-10 Erythropoietin receptor binding antibodies
PCT/US2003/032243 WO2004035603A2 (en) 2002-10-14 2003-10-14 Erythropoietin receptor binding antibodies

Publications (1)

Publication Number Publication Date
BR0315275A true BR0315275A (en) 2005-08-30

Family

ID=32109805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315275-8A BR0315275A (en) 2002-10-14 2003-10-14 Antibodies that bind to erythropoietin receptor

Country Status (13)

Country Link
EP (1) EP1578779A4 (en)
JP (2) JP4411472B2 (en)
KR (1) KR20050059263A (en)
CN (1) CN103524618A (en)
AU (2) AU2003282588B2 (en)
BR (1) BR0315275A (en)
CA (1) CA2501984C (en)
MX (1) MXPA05003997A (en)
NZ (1) NZ539263A (en)
PL (1) PL379985A1 (en)
TW (1) TWI320716B (en)
WO (1) WO2004035603A2 (en)
ZA (1) ZA201004902B (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002356844C1 (en) * 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
ES2533492T3 (en) * 2004-02-06 2015-04-10 University Of Massachusetts Antibodies against Clostridium difficile toxins and their uses
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
EP2816059A1 (en) 2008-05-01 2014-12-24 Amgen, Inc Anti-hepcidin antibodies and methods of use
JP2012500818A (en) * 2008-08-28 2012-01-12 エフ．ホフマン−ラ ロシュ アーゲー Antibody against human EPO receptor
EP3693014A1 (en) 2008-11-13 2020-08-12 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
CN102282174B (en) 2009-01-15 2014-02-26 弗·哈夫曼-拉罗切有限公司 Antibodies against human epo receptor
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
EA032537B1 (en) 2010-06-07 2019-06-28 Эмджен Инк. Method of operation of a drug delivery device
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (en) 2011-04-20 2019-04-25 Amgen Inc. Autoinjector apparatus
AR086924A1 (en) * 2011-06-15 2014-01-29 Hoffmann La Roche HUMAN EPO ANTI-RECEIVER ANTIBODIES AND THE METHODS FOR USE
EP3335747B1 (en) 2011-10-14 2021-04-07 Amgen Inc. Injector and method of assembly
ES2780395T3 (en) 2012-11-21 2020-08-25 Amgen Inc Drug delivery device
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
JP6336564B2 (en) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド Drug cassette, auto-injector, and auto-injector system
MX359794B (en) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof.
CN113559363B (en) 2013-03-22 2023-10-31 美国安进公司 Syringe and method of assembly
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
JP7051293B2 (en) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド Drug delivery system with temperature sensing control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
KR102506249B1 (en) 2014-06-03 2023-03-03 암겐 인코포레이티드 Drug delivery system and method of use
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
JP6716566B2 (en) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド Drug delivery device with proximity sensor
ES2748750T3 (en) 2015-02-17 2020-03-17 Amgen Inc Drug delivery device with vacuum assisted clamping and / or feedback
ES2905870T3 (en) 2015-02-27 2022-04-12 Amgen Inc Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
CN105542006A (en) * 2015-12-11 2016-05-04 北京大学第一医院 Preparation method and use of anti-EPOR fusion protein antibody
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
JP7064501B2 (en) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド Drug delivery device with sterile fluid flow path and related assembly methods
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Needle insertion by overpressure
JP2020509837A (en) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド Insertion mechanism for drug delivery device
CN110446499A (en) 2017-03-20 2019-11-12 豪夫迈·罗氏有限公司 A kind of method of external glycosyl engineering erythropoiesis stimulating protein
CN110446512B (en) 2017-03-28 2022-03-18 美国安进公司 Plunger rod and syringe assembly systems and methods
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
MX2019015472A (en) 2017-06-22 2020-02-19 Amgen Inc Device activation impact/shock reduction.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
MA49626A (en) 2017-07-21 2020-05-27 Amgen Inc GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (en) 2017-08-18 2020-06-24 Amgen Inc ON-BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
CN111132711B (en) 2017-10-06 2022-07-01 安进公司 Drug delivery device with interlocking components and related assembly methods
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
MX2020005066A (en) 2017-11-16 2020-08-20 Amgen Inc Autoinjector with stall and end point detection.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
MA53724A (en) 2018-09-24 2021-12-29 Amgen Inc INTERVENTIONAL DOSING SYSTEMS AND METHODS
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (en) 2018-10-02 2021-06-02 Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH INTERNAL FORCE TRANSMISSION
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
AU3492497A (en) * 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies

Also Published As

Publication number Publication date
WO2004035603A2 (en) 2004-04-29
ZA201004902B (en) 2012-06-27
EP1578779A2 (en) 2005-09-28
TW200418505A (en) 2004-10-01
AU2003282588A1 (en) 2004-05-04
CN103524618A (en) 2014-01-22
AU2003282588B2 (en) 2010-06-03
KR20050059263A (en) 2005-06-17
AU2010214778A1 (en) 2010-09-23
JP2009149665A (en) 2009-07-09
PL379985A1 (en) 2006-11-27
MXPA05003997A (en) 2005-06-22
JP4411472B2 (en) 2010-02-10
EP1578779A4 (en) 2011-11-16
TWI320716B (en) 2010-02-21
CA2501984A1 (en) 2004-04-29
WO2004035603A3 (en) 2006-04-27
NZ539263A (en) 2009-07-31
JP2006523083A (en) 2006-10-12
CA2501984C (en) 2011-04-26

Similar Documents

Publication Publication Date Title
BR0315275A (en) Antibodies that bind to erythropoietin receptor
BRPI0512352A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
TR200100267T2 (en) Substituted anilide compositions and methods.
MA30497B1 (en) ANTIBODIES AND IMMUNO-CONJUGATES, AND THEIR USES.
DE50306232D1 (en) AMPHOLYTIC COPOLYMER AND ITS USE
MY163480A (en) Sclerostin binding agents
BR0308339A (en) Indazoles Replaced with Anticancer Activity
NO20061845L (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
TW200621244A (en) Modulators of muscarinic receptors
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
BR0313676A (en) Pyrimidine derivatives and their use as cb2 modulators
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
DE60233234D1 (en) Sulfoniumsalze als photoinitiatoren für strahlungshärtbare systeme
NO20083895L (en) Anti-IGF-1R human monoclonal antibody formulation
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
MXPA05002489A (en) Branched alcohol-based personal care compositions.
NO20073369L (en) Modulators of muscarinic receptors
EA200870058A1 (en) COMPOSITIONS CONTAINING OSTEOPONTINE CATTLE, TO IMPROVE THE HEALING PROCESS OF THE RAS
BR0307518A (en) Pharmaceutical Composition
PT1107793E (en) DEXTRANE-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED PROCESSES
ATE247130T1 (en) UROKINASE RECEPTOR INHIBITORS
BR9806193A (en) Bi-aromatic composition linked by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing them
GB0324656D0 (en) A protein involved in ovarian cancer
DK0977871T3 (en) Neurotrypsin
ATE437846T1 (en) CYCLOOCT (EN-)YL DERIVATIVES FOR USE AS FRAGRANCES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained